Shanghai Shyndec Pharmaceutical (600420.SH): Sodium Bicarbonate Injection Increases Specifications and Passes Generic Drug Consistency Evaluation.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd. (referred to as Guoyao Rongsheng), recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the increase in specification of sodium bicarbonate injection and passing the generic drug quality and efficacy consistency evaluation (referred to as consistency evaluation), and issuing the drug approval number. It is reported that sodium bicarbonate injection is an anti-acid drug, with the following indications: (1) treatment of metabolic acidosis; (2) used for the prevention of uric acid kidney stones, reducing the nephrotoxicity of sulfonamide drugs, and preventing acute hemolysis from depositing hemoglobin in the renal tubules; (3) intravenous infusion has a non-specific therapeutic effect on certain drug poisonings, such as barbiturates, salicylates, and methanol poisoning.